Histamine Toxicity Market Size & Share, by Drug Type (Anti-histamines, Others); Route of Administration (Tropical, Oral, Nasal); Distribution Channel (Hospital Pharmacies, Online Pharmacies, OTC Drug Shops) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5462
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Companies Dominating the Histamine Toxicity Landscape

top-features-companies
    • Johnson and Johnson company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Mylan Laboratories Ltd
    • Neogen Corporation
    • Pfizer Inc
    • Travere Therapeutics, Inc.
    • Alembic pharmaceuticals
    • Intas Pharmaceuticals Ltd
    • Sanofi Aventis Ltd
    • Cipla Limited
    • Actavis Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Two new tests to detect Histamine have been launched by Neogen, Reveal for histamine and Reveal Q+ for histamine. Reveal and Reveal Q+ assays are easy to use lateral flow tests using a simple water extraction method, providing results in a matter of minutes and eliminating the need to dispose of any chemicals, as is required by other commercially available histamine detection methods, which reduce the time needed to test.
  • Travere Therapeutics, Inc. reported that the US Food and Drug Administration granted accelerated approval for FILSPARRI to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression, typically with a urine protein-to-creatinine ratio ≥1.5 g/g. This indication is given with accelerated approval based on reduction of proteinuria. It has not been established whether FILSPARI slows the decline in renal function in patients with IgAN. Continued approval of FILSPARI may require confirmation of clinical benefit in the ongoing Phase 3 PROTECT study, which is designed to show whether FILSPARI slows the decline in kidney function. Peak results from the two-year confirmatory endpoint of the PROTECT study are expected in the fourth quarter of 2023 and are intended to support traditional FILSPAR approval.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5462
  • Published Date: Dec 18, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing consumption of seafood, poor refrigeration & rotten fish are some of the major factors anticipated to drive the growth of the histamine toxicity market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Travere Therapeutics, Inc., Alembic pharmaceuticals, Intas Pharmaceuticals Ltd, Sanofi Aventis Ltd, Cipla Limited, Actavis Inc., and others.

The anti-histamine segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying